. Author manuscript; available in PMC: 2021 May 4.

Published in final edited form as: Stat Methods Med Res. 2019 Aug 22;29(6):1573–1591. doi: 10.1177/0962280219869364

Table 3.

Estimates and standard errors for select parameters from analyses of the CIBMTR HCT data (n= 9,651) including: the proposed finite interval illness-death model with frailty, assuming Weibull ( $FI - {ID}_{WB}^{γ}$ ) and B-spline ( $FI - {ID}_{BS}^{γ}$ ) baseline hazard functions described in Section 3.4; the cure fraction illness-death model of Conlon et al.³¹ with an additional frailty (Conlon^γ); the illness-death model with frailty (ID^γ); the cure fraction model for acute GVHD; and a multi-state illness-death model (MSM), which aligns with the results of a univariate Cox model for acute GVHD on the transition from HCT to acute GVHD.

	$FI - {ID}_{WB}^{γ}$		$FI - {ID}_{BS}^{γ}$		Conlon^γ		ID^γ		Cure		MSM
	Est	SE	Est	SE	Est	SE	Est	SE	Est	SE	Est	SE
Non-susceptible fraction
Intercept	1.94	0.06	1.90	0.07	2.07	0.06			1.99	0.06
Intermediate stage	−0.14	0.07	−0.18	0.07	−0.15	0.07			−0.08	0.07
Advanced stage	−0.33	0.08	−0.54	0.08	−0.35	0.08			−0.25	0.07
HLA: 7/8	−0.75	0.08	−0.76	0.08	−0.77	0.09			−0.69	0.08
HLA: 8/8	−0.42	0.07	−0.43	0.06	−0.47	0.07			−0.40	0.06
Disease type: ALL	−0.17	0.08	−0.19	0.07	−0.20	0.08			−0.06	0.07
Disease type: CML	−0.44	0.08	−0.39	0.08	−0.49	0.08			−0.38	0.08
Disease type: MDS	−0.25	0.10	−0.15	0.09	−0.29	0.10			−0.21	0.09
Non-susceptible: HCT → Death
Intermediate stage	0.30	0.06	0.25	0.06	0.27	0.06
Advanced stage	1.13	0.06	0.94	0.05	1.05	0.06
HLA: 7/8	0.32	0.07	0.26	0.06	0.31	0.07
HLA: 8/8	0.14	0.05	0.10	0.05	0.11	0.05
Disease type: ALL	−0.08	0.06	−0.11	0.06	−0.09	0.06
Disease type: CML	−0.53	0.09	−0.51	0.08	−0.52	0.08
Disease type: MDS	−0.52	0.08	−0.44	0.07	−0.50	0.08
Susceptible: HCT → Death
Intermediate stage	−0.04	0.20	0.35	0.17	0.68	0.36	0.43	0.13			0.30	0.05
Advanced stage	0.20	0.22	0.89	0.16	1.24	0.37	1.63	0.13			1.00	0.05
HLA: 7/8	0.68	0.21	0.46	0.17	1.29	0.50	1.55	0.15			0.34	0.05
HLA: 8/8	0.37	0.19	0.37	0.15	1.20	0.47	1.02	0.12			0.15	0.04
Disease type: ALL	0.64	0.20	0.54	0.14	1.37	0.43	0.49	0.14			0.00	0.05
Disease type: CML	0.07	0.23	0.02	0.19	1.09	0.48	0.08	0.16			−0.37	0.07
Disease type: MDS	0.11	0.27	−0.09	0.18	0.75	0.47	−0.04	0.17			−0.40	0.06
Susceptible: HCT → Acute GVHD
Intermediate stage	−0.30	0.09	−0.27	0.07	−0.30	0.08	0.01	0.11	−0.21	0.07	0.05	0.06
Advanced stage	−0.24	0.10	−0.31	0.08	−0.22	0.08	0.51	0.11	−0.10	0.06	0.21	0.06
HLA: 7/8	0.44	0.11	0.32	0.08	0.42	0.10	1.24	0.13	0.47	0.07	0.66	0.07
HLA: 8/8	0.44	0.09	0.27	0.06	0.37	0.08	0.87	0.10	0.37	0.06	0.40	0.06
Disease type: ALL	0.12	0.10	0.06	0.07	0.09	0.09	0.33	0.12	0.19	0.07	0.07	0.07
Disease type: CML	0.12	0.10	0.10	0.07	0.09	0.09	0.63	0.13	0.14	0.07	0.35	0.07
Disease type: MDS	0.04	0.12	0.08	0.09	0.02	0.10	0.33	0.14	0.12	0.08	0.19	0.08
Susceptible: Acute GVHD → Death
Intermediate stage	0.15	0.09	0.13	0.08	0.15	0.09	0.33	0.13			0.13	0.08
Advanced stage	0.59	0.09	0.51	0.07	0.58	0.08	1.22	0.13			0.51	0.07
HLA: 7/8	0.29	0.10	0.26	0.09	0.29	0.09	0.85	0.14			0.25	0.09
HLA: 8/8	0.08	0.08	0.09	0.07	0.09	0.08	0.37	0.12			0.08	0.07
Disease type: ALL	0.01	0.10	0.01	0.08	0.01	0.09	0.12	0.14			0.01	0.08
Disease type: CML	0.15	0.10	0.12	0.09	0.15	0.10	0.42	0.14			0.13	0.09
Disease type: MDS	0.11	0.11	0.07	0.10	0.09	0.10	0.30	0.16			0.07	0.10
Log-frailty variance
log(θ)	−0.89	0.08	−4.76	1.88	−1.47	0.15	2.31	0.04